Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBM-02 in Newly Diagnosed Glioblastoma
NCT04874506Phase 2Unknown
- Sponsor
- Matrix Biomed, Inc.
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MBI-05-01 in glioblastoma multiforme (GBM) (4 cohorts), sponsored by Matrix Biomed, Inc. Primary endpoint: Progression Free Survival at 6 months. Status: unknown.
02
Drugs
MBI-05-01
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04874506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874506.